Intranasal Vaccination with M2e5x Virus-like Particles Induces Humoral and Cellular Immune Responses Conferring Cross-protection Against Heterosubtypic Influenza Viruses

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Jan 12

PMID 29324805

Citations 40

Authors

Young-Tae Lee

Eun-Ju Ko

Youri Lee

Ki-Hye Kim

Min-Chul Kim

Yu-Na Lee

Sang-Moo Kang

Affiliations

Soon will be listed here.

Abstract

Current influenza vaccines do not provide broad cross-protection. Here, we report that intranasal vaccination with virus-like particles containing the highly conserved multiple ectodomains of matrix protein 2 (M2e5x VLP) of influenza virus induces broad cross-protection by M2-specific humoral and cellular immune responses. M2e5x VLP intranasal vaccination prevented severe weight loss, attenuated inflammatory cytokines and cellular infiltrates, and lowered viral loads, and induced germinal center phenotypic B and plasma cells. In addition, depletion studies demonstrate the protective roles of CD4 and CD8 T cells induced by M2e5x VLP intranasal vaccination. Thus, this study provides evidence that mucosal delivery of M2e5x VLP vaccine provides cross-protection by inducing humoral and cellular immune responses.

Citing Articles

Multifaceted virus-like particles: Navigating towards broadly effective influenza A virus vaccines.

Norizwan J, Tan W Curr Res Microb Sci. 2024; 8:100317.

PMID: 39717209 PMC: 11665419. DOI: 10.1016/j.crmicr.2024.100317.

Strengths and limitations of SARS-CoV-2 virus-like particle systems.

Sultana R, Stahelin R Virology. 2024; 601:110285.

PMID: 39536645 PMC: 11624109. DOI: 10.1016/j.virol.2024.110285.

Generation of antigen-specific memory CD4 T cells by heterologous immunization enhances the magnitude of the germinal center response upon influenza infection.

Sircy L, Ramstead A, Gibbs L, Joshi H, Baessler A, Mena I PLoS Pathog. 2024; 20(9):e1011639.

PMID: 39283916 PMC: 11404825. DOI: 10.1371/journal.ppat.1011639.

Plant-Produced Chimeric Hepatitis E Virus-like Particles as Carriers for Antigen Presentation.

Mardanova E, Vasyagin E, Kotova K, Zahmanova G, Ravin N Viruses. 2024; 16(7).

PMID: 39066255 PMC: 11281382. DOI: 10.3390/v16071093.

The Potential of Plant-Produced Virus-like Particle Vaccines for African Horse Sickness and Other Equine Orbiviruses.

Pitchers K, Boakye O, Campeotto I, Daly J Pathogens. 2024; 13(6).

PMID: 38921755 PMC: 11206403. DOI: 10.3390/pathogens13060458.

References

Jegerlehner A, Schmitz N, Storni T, Bachmann M . Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004; 172(9):5598-605. DOI: 10.4049/jimmunol.172.9.5598. View

Fan J, Liang X, Horton M, Perry H, Citron M, Heidecker G . Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine. 2004; 22(23-24):2993-3003. DOI: 10.1016/j.vaccine.2004.02.021. View

Osterholm M . Preparing for the next pandemic. N Engl J Med. 2005; 352(18):1839-42. DOI: 10.1056/NEJMp058068. View

Wu F, Yuan X, Li J, Chen Y . The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. Vaccine. 2009; 27(32):4320-4. DOI: 10.1016/j.vaccine.2009.04.075. View

Song J, Kim Y, Barlow P, Hossain M, Park K, Donis R . Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res. 2010; 88(2):244-7. PMC: 2980851. DOI: 10.1016/j.antiviral.2010.09.001. View

Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W . A "universal" human influenza A vaccine. Virus Res. 2004; 103(1-2):173-6. DOI: 10.1016/j.virusres.2004.02.030. View

Pasare C, Medzhitov R . Control of B-cell responses by Toll-like receptors. Nature. 2005; 438(7066):364-8. DOI: 10.1038/nature04267. View

Brito L, Singh M . Acceptable levels of endotoxin in vaccine formulations during preclinical research. J Pharm Sci. 2010; 100(1):34-7. DOI: 10.1002/jps.22267. View

Wang L, Wang Y, Feng H, Ahmed T, Compans R, Wang B . Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterosubtypic protection in mice. Biomed Res Int. 2013; 2013:686549. PMC: 3745920. DOI: 10.1155/2013/686549. View

10.

Szretter K, Gangappa S, Lu X, Smith C, Shieh W, Zaki S . Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol. 2006; 81(6):2736-44. PMC: 1866007. DOI: 10.1128/JVI.02336-06. View

11.

Lee Y, Ko E, Lee Y, Lee Y, Bian Z, Liu Y . CD47 Plays a Role as a Negative Regulator in Inducing Protective Immune Responses to Vaccination against Influenza Virus. J Virol. 2016; 90(15):6746-6758. PMC: 4944296. DOI: 10.1128/JVI.00605-16. View

12.

Viboud C, Miller M, Olson D, Osterholm M, Simonsen L . Preliminary Estimates of Mortality and Years of Life Lost Associated with the 2009 A/H1N1 Pandemic in the US and Comparison with Past Influenza Seasons. PLoS Curr. 2010; 2:RRN1153. PMC: 2843747. DOI: 10.1371/currents.rrn1153. View

13.

Bessa J, Schmitz N, Hinton H, Schwarz K, Jegerlehner A, Bachmann M . Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol. 2007; 38(1):114-26. DOI: 10.1002/eji.200636959. View

14.

Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H . Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Arch Virol. 2010; 155(4):535-44. DOI: 10.1007/s00705-010-0621-4. View

15.

Suarez-Ramirez J, Wu T, Lee Y, Aguila C, Bouchard K, Cauley L . Division of labor between subsets of lymph node dendritic cells determines the specificity of the CD8⁺ T-cell recall response to influenza infection. Eur J Immunol. 2011; 41(9):2632-41. PMC: 3517118. DOI: 10.1002/eji.201141546. View

16.

Brown D, Lee S, Garcia-Hernandez M, Swain S . Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol. 2012; 86(12):6792-803. PMC: 3393557. DOI: 10.1128/JVI.07172-11. View

17.

Pei S, Xiong N, Zhang Y, Chen S . Increasing M2 epitope density enhances systemic and mucosal immune responses to influenza A virus. Biotechnol Lett. 2009; 31(12):1851-6. DOI: 10.1007/s10529-009-0102-6. View

18.

Heinen P, Rijsewijk F, de Boer-Luijtze E, Bianchi A . Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol. 2002; 83(Pt 8):1851-1859. DOI: 10.1099/0022-1317-83-8-1851. View

19.

Liu Q, Zhou Y, Yang Z . The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2015; 13(1):3-10. PMC: 4711683. DOI: 10.1038/cmi.2015.74. View

20.

Ernst W, Kim H, Tumpey T, Jansen A, Tai W, Cramer D . Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine. 2006; 24(24):5158-68. DOI: 10.1016/j.vaccine.2006.04.008. View